Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that target cell-signaling pathways certain cancers. It is developing its lead product candidate, tipifarnib, a farnesyl transferase inhibitor, in both solid tumors and blood cancers, with Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) mutations. Its tipifarnib has completed Phase I clinical trials. Its pipeline includes two preclinical programs. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinases 1 and 2 (ERK1/2), as a potential treatment for patients with tumors. It is also developing orally available, small molecule inhibitors of the menin-mixed lineage leukemia (menin-MLL), interaction, which are in lead optimization as a treatment for patients with acute leukemias.
